Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides - Takeaways - MDSpire

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

  • By

  • Sheng-Guang Li

  • Yadan Zou

  • Ji Li

  • Lina Zhang

  • Jing Zhang

  • Ting Long

  • Ruohan Yu

  • Yanfeng Zhang

  • June 4, 2026

  • 0 min

Share

  • 1

    Immune-mediated inflammatory arthritides (IMIA) increase cancer susceptibility due to persistent inflammation and other risk factors.

  • 2

    Biologic therapies generally show reassuring safety profiles regarding malignancy, though non-melanoma skin cancer is a notable exception.

  • 3

    JAK inhibitors require caution in risk-enriched populations, particularly among older patients and those with prior malignancies.

  • 4

    Recent studies indicate comparable overall cancer incidence between JAK inhibitors and TNF inhibitors, with specific cancers more frequent in certain groups.

  • 5

    Management of malignancy risk in IMIA should be individualized, balancing the need for inflammation control with oncologic vulnerability.

Original Source(s)

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

  • by Sheng-Guang Li, Yadan Zou, Ji Li, Lina Zhang, Jing Zhang, Ting Long, Ruohan Yu, Yanfeng Zhang

  • June 4, 2026

Related Content

Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

Neutrophil extracellular traps and pyroptosis: a molecular nexus linking systemic autoimmune diseases to atherosclerosis

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.